Phase I/II trial of association of sorafenib in combination with temozolomide in patients with metastatic melanoma: Looking for predictive markers of efficacy.

C. Robert,Nathalie Chaput,N. Lassau,Anne Auperin,Serge Koscielny,E. Hollville,Vladimir Lazar,Ludovic Lacroix,Jeannette Soria,C. Mateus

Phase I/II trial of association of sorafenib in combination with temozolomide in patients with metastatic melanoma: Looking for predictive markers of efficacy.

2010

C. Robert
Nathalie Chaput
N. Lassau
Anne Auperin
Serge Koscielny
E. Hollville
Vladimir Lazar
Ludovic Lacroix
Jeannette Soria
C. Mateus

8552 Background: The poor activity of treatments (tt) against metastatic melanoma (MM) mainly relies in the absence of predictive markers of efficacy that could allow selection of responsive pts. T...

Keywords:

Melanoma
Physical therapy
Temozolomide
Sorafenib
Medicine
Oncology
metastatic melanoma
phase i ii
Internal medicine
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations